A rare case of pulmonary mucormycosis complicated by hydropneumothorax, successfully treated with non-surgical therapies.
Qiliang LiuWilliam GoodAndrew SalmonNicholas GowPaul GriffithsPublished in: Respirology case reports (2022)
Pulmonary mucormycosis (PM) is a rare but rapidly progressive fungal infection associated with high mortality. A review of the literature suggests that pleural effusions and pneumothoraces are uncommon manifestations associated with distant dissemination. Combined surgical interventions and prolonged antifungal therapy constitute the standard first-line management, with significantly poorer outcomes seen in patients managed with medical therapy alone. Here, we report an unusual case of PM complicated by hydropneumothorax in an immunocompromised patient, in whom comorbidities and disease burden precluded surgical debridement. His disease was ultimately treated with intravenous amphotericin B and maintenance posaconazole after adjunctive drainage. This clinical experience highlights the efficacy of antifungal therapy alone in the treatment of potentially fatal cases of PM unsuitable for surgery.
Keyphrases
- particulate matter
- rare case
- air pollution
- pulmonary hypertension
- candida albicans
- healthcare
- multiple sclerosis
- polycyclic aromatic hydrocarbons
- ejection fraction
- lymph node
- prognostic factors
- risk factors
- high dose
- physical activity
- stem cells
- cardiovascular events
- water soluble
- cardiovascular disease
- type diabetes
- low dose
- coronary artery disease
- intensive care unit
- chronic kidney disease
- coronary artery bypass
- percutaneous coronary intervention
- skeletal muscle
- atrial fibrillation
- patient reported